📊 Midday Market Take

Hey there, hope your Thursday is going well, because the market sure is. The S&P 500 is up 0.77%, the Nasdaq is climbing 1.07%, and even the Dow is tagging along with a solid 0.34% gain.

Tech is doing the heavy lifting today, pulling the Nasdaq ahead of its peers with real conviction. Keep an eye on whether that momentum holds into the final hour, because afternoon profit-taking has a way of showing up uninvited.

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease.

3 Reasons to Watch BBIO

• Attruby Just Got a Lot More Interesting. New data shows acoramidis, the active compound in BridgeBio's Attruby, is associated with direct kidney-protective effects in ATTR-CM patients, a benefit that goes well beyond the heart. That kind of expanded clinical profile could meaningfully widen the drug's commercial appeal and give prescribers another reason to reach for it first.
• The Stock Is Up 97% in a Year and Still Moving. BBIO has nearly doubled over the past 12 months, and it is not slowing down, with shares up more than 36% in just the last 30 days alone. A 15.70% single-day jump tells you the market is actively repricing this one, not just holding it.
• A Deep Pipeline Makes the Risk Conversation Complicated. BridgeBio has multiple drugs in Phase 3 across rare diseases including achondroplasia, hypoparathyroidism, and limb-girdle muscular dystrophy, which means upcoming trial readouts could swing the stock hard in either direction. Investors debating whether BBIO is too expensive right now are really debating which of those catalysts they believe in most.

Top Market Headlines

2 Drone Stocks for Your Watchlist

AERG and UAVS offer drone and anti-drone technologies.

You must do this before the OpenAI IPO (Ad)

Millions of investors are getting ready to buy OpenAI the moment it goes public. But that could be too late. Instead, there's a way anyone can claim a pre-IPO ownership stake NOW starting with just a few hundred dollars.

Broadcom and Nvidia Just Made Morningstar's ‘Cheap Stocks to Buy' List

Nvidia Corp. (NASDAQ:NVDA) and Broadcom Inc. (NASDAQ:AVGO) just landed on Morningstar's latest "Cheap Stocks to Buy" list, putting two of the...

These 2 Oils and Energy Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Don't download this book (seriously) (Ad)

Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It outlines the approach he developed after losing a small fortune on complex strategies. The book covers a straightforward technique that he says consistently outperforms complicated methods, including how to evaluate any trade in under 10 minutes.tc pixel

Broadcom, Intel, Corning, Marvell, and More Stocks That Explain Today's Market

The AI trade mounts a comeback as investors get over the worst of their fears about a flare-up in tensions between the U.S. and Iran.

Trump's $250,000/Month Secret Exposed (Ad)

While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies...

📈 Also Trending

Elon Just Spent $60 Billion of SpaceX Stock on What?! (Ad)

SpaceX has only been public for a couple weeks, and Elon's already closed his first multi-billion-dollar deal. But the media is missing the massive economic implications of this historic deal.

Click here to find out what it means for you and your money.

New Musk product worth 684X Starlink? (Ad)

Early Starlink investors could have turned $1,000 into over $64.5 million… But Wall Street's latest estimates say Musk's new AI product could be worth 684X Starlink. And Jeff Brown says it could...

Click Here for the Full Story.

AI Just Signed the Dollar's Death Warrant (Ad)

AI isn't just writing emails and creating videos. It's being wired into the financial system itself… moving faster than anyone in the world can control. And every breakthrough pushes us closer to one thing: A fully digital, government-issued dollar. A CBDC. Once that switch flips, the rules change o...

Click to see more and claim your free guide ->